Hepatic ductular reaction: a double-edged sword

por Sun, Tianliang, Annunziato, Stefano, Tchorz, Jan S.
Publicado 2019

Prometheus revisited: liver homeostasis and repair

por Sun, Tianliang, Annunziato, Stefano, Tchorz, Jan S.
Publicado 2020

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance

por Hoogstraat, Marlous, Lips, Esther H., Mayayo-Peralta, Isabel, Mulder, Lennart, Kristel, Petra, van der Heijden, Ingrid, Annunziato, Stefano, van Seijen, Maartje, Nederlof, Petra M., Sonke, Gabe S., Zwart, Wilbert, Wesseling, Jelle, Wessels, Lodewyk F. A.
Publicado 2022

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland

por Annunziato, Stefano, Kas, Sjors M., Nethe, Micha, Yücel, Hatice, Del Bravo, Jessica, Pritchard, Colin, Bin Ali, Rahmen, van Gerwen, Bas, Siteur, Bjørn, Drenth, Anne Paulien, Schut, Eva, van de Ven, Marieke, Boelens, Mirjam C., Klarenbeek, Sjoerd, Huijbers, Ivo J., van Miltenburg, Martine H., Jonkers, Jos
Publicado 2016

Cell adhesion molecule KIRREL1 is a feedback regulator of Hippo signaling recruiting SAV1 to cell-cell contact sites

por Paul, Atanu, Annunziato, Stefano, Lu, Bo, Sun, Tianliang, Evrova, Olivera, Planas-Paz, Lara, Orsini, Vanessa, Terracciano, Luigi M., Charlat, Olga, Loureiro, Zinger Yang, Ji, Lei, Zamponi, Raffaella, Sigoillot, Frederic, Lei, Hong, Lindeman, Alicia, Russ, Carsten, Reece-Hoyes, John S., Nicholson, Thomas B., Tchorz, Jan S., Cong, Feng
Publicado 2022

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

por Barazas, Marco, Annunziato, Stefano, Pettitt, Stephen J., de Krijger, Inge, Ghezraoui, Hind, Roobol, Stefan J., Lutz, Catrin, Frankum, Jessica, Song, Fei Fei, Brough, Rachel, Evers, Bastiaan, Gogola, Ewa, Bhin, Jinhyuk, van de Ven, Marieke, van Gent, Dik C., Jacobs, Jacqueline J.L., Chapman, Ross, Lord, Christopher J., Jonkers, Jos, Rottenberg, Sven
Publicado 2018

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

por Annunziato, Stefano, de Ruiter, Julian R., Henneman, Linda, Brambillasca, Chiara S., Lutz, Catrin, Vaillant, François, Ferrante, Federica, Drenth, Anne Paulien, van der Burg, Eline, Siteur, Bjørn, van Gerwen, Bas, de Bruijn, Roebi, van Miltenburg, Martine H., Huijbers, Ivo J., van de Ven, Marieke, Visvader, Jane E., Lindeman, Geoffrey J., Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2019

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

por Bhin, Jinhyuk, Yemelyanenko, Julia, Chao, Xue, Klarenbeek, Sjoerd, Opdam, Mark, Malka, Yuval, Hoekman, Liesbeth, Kruger, Dinja, Bleijerveld, Onno, Brambillasca, Chiara S., Sprengers, Justin, Siteur, Bjørn, Annunziato, Stefano, van Haren, Matthijs J., Martin, Nathaniel I., van de Ven, Marieke, Peters, Dennis, Agami, Reuven, Linn, Sabine C., Boven, Epie, Altelaar, Maarten, Jonkers, Jos, Zingg, Daniel, Wessels, Lodewyk F.A.
Publicado 2023

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

por ter Brugge, Petra, Moser, Sarah C., Bièche, Ivan, Kristel, Petra, Ibadioune, Sabrina, Eeckhoutte, Alexandre, de Bruijn, Roebi, van der Burg, Eline, Lutz, Catrin, Annunziato, Stefano, de Ruiter, Julian, Masliah Planchon, Julien, Vacher, Sophie, Courtois, Laura, El-Botty, Rania, Dahmani, Ahmed, Montaudon, Elodie, Morisset, Ludivine, Sourd, Laura, Huguet, Léa, Derrien, Heloise, Nemati, Fariba, Chateau-Joubert, Sophie, Larcher, Thibaut, Salomon, Anne, Decaudin, Didier, Reyal, Fabien, Coussy, Florence, Popova, Tatiana, Wesseling, Jelle, Stern, Marc-Henri, Jonkers, Jos, Marangoni, Elisabetta
Publicado 2023

The Shieldin complex mediates 53BP1-dependent DNA repair

por Noordermeer, Sylvie M., Adam, Salomé, Setiaputra, Dheva, Barazas, Marco, Pettitt, Stephen J., Ling, Alexanda K., Olivieri, Michele, Álvarez-Quilón, Alejandro, Moatti, Nathalie, Zimmermann, Michal, Annunziato, Stefano, Krastev, Dragomir B., Song, Feifei, Brandsma, Inger, Frankum, Jessica, Brough, Rachel, Sherker, Alana, Landry, Sébastien, Szilard, Rachel K., Munro, Meagan M., McEwan, Andrea, Goullet de Rugy, Théo, Lin, Zhen-Yuan, Hart, Traver, Moffat, Jason, Gingras, Anne-Claude, Martin, Alberto, van Attikum, Haico, Jonkers, Jos, Lord, Christopher J., Rottenberg, Sven, Durocher, Daniel
Publicado 2018

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

por Zimmerli, Dario, Brambillasca, Chiara S., Talens, Francien, Bhin, Jinhyuk, Linstra, Renske, Romanens, Lou, Bhattacharya, Arkajyoti, Joosten, Stacey E. P., Da Silva, Ana Moises, Padrao, Nuno, Wellenstein, Max D., Kersten, Kelly, de Boo, Mart, Roorda, Maurits, Henneman, Linda, de Bruijn, Roebi, Annunziato, Stefano, van der Burg, Eline, Drenth, Anne Paulien, Lutz, Catrin, Endres, Theresa, van de Ven, Marieke, Eilers, Martin, Wessels, Lodewyk, de Visser, Karin E., Zwart, Wilbert, Fehrmann, Rudolf S. N., van Vugt, Marcel A. T. M., Jonkers, Jos
Publicado 2022

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022